Zibotentan/Dapagliflozin Combination Demonstrated Significant Albuminuria Reduction In Patients With Chronic Kidney Disease And Proteinuria In ZENITH-CKD Phase IIb Trial
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca's combination of zibotentan and dapagliflozin has shown significant albuminuria reduction in patients with chronic kidney disease and proteinuria in the ZENITH-CKD Phase IIb trial. The results were presented at the American Society of Nephrology Kidney Week 2023 and simultaneously published in The Lancet. The combination showed statistically significant and clinically meaningful reductions in urinary albumin-to-creatinine ratio (UACR) at 12 weeks compared with dapagliflozin alone. AstraZeneca plans to start Phase III trials in Q4 2023.
November 03, 2023 | 3:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's zibotentan/dapagliflozin combination has shown promising results in Phase IIb trials, potentially leading to a new treatment for chronic kidney disease. This could boost the company's product portfolio and future revenues if the drug is approved.
The positive results from the Phase IIb trial of AstraZeneca's zibotentan/dapagliflozin combination indicate a potential new treatment for chronic kidney disease. If the drug is approved in the future, it could significantly boost AstraZeneca's product portfolio and revenues, positively impacting the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100